Key result
Recent advances in the pathological and molecular characterization of retroperitoneal sarcomas have led to major changes in diagnostic management and new therapeutic strategies.
Why the study?
Significant advances in the pathological and molecular characterization of retroperitoneal sarcomas have led to major changes in diagnostic management and the development of new biology-based therapeutic strategies.
This review summarizes recent advances in the pathological and molecular characterization of retroperitoneal sarcomas, which inform diagnostic and therapeutic strategies.
May inform diagnostic workflows for retroperitoneal sarcomas; leaves open prospective validation of emerging therapies.
Retroperitoneal sarcomas (RPS) refer to a heterogeneous group of malignancies of mesenchymal origin developing from retroperitoneal tissues and vessels. The most frequent RPS are well differentiated/dedifferentiated liposarcomas and leiomyosarcomas, but other rare histological subtypes can be observed. Over the last decade, significant advances have been made in the pathological and molecular characterization of sarcomas. These advances have led to major changes in their diagnostic management as well as in the development of new therapeutic strategies based on tumor biology and microenvironment. This review describes the current knowledge and recent findings in the pathology and molecular biology of the most frequent RPS subtypes.
No takes yet. Share an insight, caveat, or question.
Watson et al. (2022) conducted a review in Retroperitoneal sarcomas. Recent advances in the pathological and molecular characterization of retroperitoneal sarcomas have led to major changes in diagnostic management and new therapeutic strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: